-
Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
05 Sep 2025 11:00 GMT
… IL-2, IL-4 and IL-13 Superkines and first-in-class … and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and …
-
Medicenna Presents at National Brain Tumor Society’s Research Round Table
25 Jul 2023 11:26 GMT
… the Brain Cancer Research Roundtable organized by the National Brain Tumor Society … organized by the National Brain Tumor Society (NBTS). The event … 2, IL-4 and IL-13 Superkines and first in … Our focus on defeating brain tumors and improving the quality …
-
Medicenna Presents at National Brain Tumor Society's Research Round Table
25 Jul 2023 11:00 GMT
… the Brain Cancer Research Roundtable organized by the National Brain Tumor Society … organized by the National Brain Tumor Society (NBTS). The event … 2, IL-4 and IL-13 Superkines and first in … Our focus on defeating brain tumors and improving the quality …
-
Identification and Experimental Validation of Oxidative Stress-Related Biomarkers in Ulcerative Colitis Using Machine Learning
20 Aug 2025 13:32 GMT
… pro-inflammatory reprogramming driven by IL-13/STAT6 signaling.53 The … prediction models for one-year brain tumour survival using machine learning: a …
-
Clinical trial approved by FDA for glioblastoma brain cancer
16 Mar 2022 01:45 GMT
… recurrent glioblastoma, a type of brain cancer. The phase I trial is … of the IL-4 and IL-13 cytokine receptor complex. This therapeutic …
-
Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting
17 Apr 2023 11:00 GMT
… characterizing the Interleukin 13 (IL-13) Superkines, MDNA132 and … ability of our IL-13 Superkines to preferentially … Characterization of MDNA132, an IL-13 Decoy Receptor Selective Superkine … uniformly fatal form of brain cancer. Bizaxofusp has obtained …
-
Medicenna strengthens IP portfolio with five patents granted for its IL─2 and IL─4 Superkines
02 Aug 2025 06:50 GMT
… commercial exclusivity for treatment of brain cancers as we pursue potential partnering … IL-2, IL-4 and IL-13 Superkines and first-in-class …
-
Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights
01 Aug 2025 11:00 GMT
… IL-2, IL-4 and IL-13 Superkines and first-in-class … and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and …
-
Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines
31 Jul 2025 11:00 GMT
… commercial exclusivity for treatment of brain cancers as we pursue potential partnering … IL-2, IL-4 and IL-13 Superkines and first-in-class … and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and …
-
Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022
22 Sep 2022 11:30 GMT
… cancer
--IL-4/IL-13 Super-antagonist displayed monotherapy activity … domain linked to wild type IL-13. This superior binding profile … inhibit IL-4/IL-13 mediated functions as measured by … and uniformly fatal form of brain cancer. MDNA55 has obtained Fast …
About
© 1995-2025